Other languages Lepu Biopharma Co., Ltd.

Equities

2157

CNE100004SM4

Delayed Hong Kong S.E. Other stock markets 07:19:51 10/05/2024 am IST			5-day change	1st Jan Change
5.71 ^HKD	+4.01%		-7.27%	+36.34%

12/04	Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	MT
27/03	Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	12/04
Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Lepu Biopharma's Pancreatic Cancer Drug Gets US FDA Fast-Track Designation	11/03
Lepu Biopharma Co., Ltd. Receives Fast Track Designation by the Food and Drug Administration of the United States for the Treatment of Pancreatic Cancer	11/03
Lepu Biopharma Co., Ltd. Announces Completion of Patient Enrollment of Pivotal Phase IIb Clinical Trial for MRG003 for the Treatment of R/M NPC	29/12
Lepu Biopharma Co., Ltd. Announces Orphan-Drug Designation Granted by the FDA to MRG004A for the Treatment of Pancreatic Cancer	14/12
Lepu Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/23/25
Stocks add to rebound; SSE ups earnings guidance	30/23/30
Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	17/23/17
AstraZeneca : accord de licence exclusif avec KYM Biosciences	23/23/23
Keymed and Lepu Biopharma Jointly Announces Global Exclusive Licence Agreement with Astrazeneca for Cmg901	23/23/23
Lepu Biopharma Co., Ltd. Provides Update on the Data from Phase Ia Clinical Study of CMG901	05/23/05
Luye Pharma's Boan Biotech Kicks Off Hong Kong IPO	19/22/19
Lepu Biopharma Co., Ltd. Announces Conditional Marketing Approval Obtained in China Forpuyouheng (Pucotenlimab Injection) for Thetreatment of Inoperable or Metastatic Melanoma	29/22/29
Lepu Biopharma Co., Ltd. Announces Breakthrough Therapy Designation Granted by the Center for Drug Evaluation to MRG003 for the Treatment of R/M NPC	29/22/29
Lepu Biopharma H1 Loss Goes Down	27/22/27
Anti-PD-1 Monoclonal Antibody Puyouheng Co-developed by LEPU BIOPHARMA and HANX BIOPHARMACEUTICALS Approved for Marketing in China by NMPA	25/22/25
Lepu Biopharma Co., Ltd. Receive Conditional Marketing Approval Obtained in China for Puyouheng (Pucotenlimab Injection) for the Treatment Inhigh Levels of Microsatellite Instability/Deficient Mismatch Repair (MSI-H/dMMR)	22/22/22
Shandong Boan Biotechnology Files for Hong Kong IPO	16/22/16
Lepu Biopharma Partially Exercises Hong Kong IPO Overallotment Option	18/22/18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lepu Biopharma Co., Ltd.

Equities

2157

CNE100004SM4

Other languages

Filters